Table 4.
Change in non-calcified coronary plaque burden over one-year between treatment groups
| Treatments | Change over one-year (mm2) (%) | P-value | |
|---|---|---|---|
| Anti-TNF therapy (n = 48) | −0.06 (−5) | – | |
| vs. Anti-IL12/23 | – | −0.02 (−2) | 0.27 |
| vs. Anti-IL17 | – | −0.15 (−12) | 0.08 |
| vs. NBT | – | 0.06 (5) | 0.009 |
| Anti-IL12/23 therapy (n = 19) | −0.02 (−2) | – | |
| vs. Anti-IL17 | – | −0.15 (−12) | 0.01 |
| vs. NBT | – | 0.06 (5) | 0.09 |
| Anti-IL17 therapy (n = 22) | −0.15 (−12) | – | |
| vs. NBT | – | 0.06 (5) | 0.005 |
Values are reported as Mean (% change) for continuous data. Two-tailed P-values less than 0.05 significant (bold values).
IL, interleukin; NBT, non-biologic treated.